Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
HEALTH
Best Biotech Stocks to Buy in 2021
By Bret Jensen
Jan 31, 2021 10:15 AM EST
PRESS RELEASES
Exelixis Announces Positive Findings At ASCO GU For CABOMETYX® (cabozantinib) In Patients With Brain Metastases From Renal Cell Carcinoma
By Business Wire
Feb 8, 2021 5:00 PM EST
PRESS RELEASES
Exelixis To Webcast Virtual Fireside Chat As Part Of The Guggenheim Healthcare Talks Oncology Day On February 11, 2021
By Business Wire
Feb 4, 2021 4:05 PM EST
PRESS RELEASES
Exelixis And Adagene Enter Into Collaboration And License Agreement To Develop Novel Masked Antibody-Drug Conjugate Therapies With Improved Safety And Efficacy Profiles
By Business Wire
Feb 1, 2021 8:00 AM EST
PRESS RELEASES
Exelixis To Release Fourth Quarter And Full Year 2020 Financial Results On Wednesday, February 10, 2021
By Business Wire
Jan 27, 2021 4:05 PM EST
PRESS RELEASES
Exelixis Announces Initiation Of Phase 1 Trial Evaluating XL102 As A Single Agent And In Combination With Other Anti-Cancer Agents In Patients With Advanced Or Metastatic Solid Tumors
By Business Wire
Jan 25, 2021 8:00 AM EST
PRESS RELEASES
Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) In Combination With OPDIVO® (nivolumab) As A First-Line Treatment For Patients With Advanced Renal Cell Carcinoma
By Business Wire
Jan 22, 2021 1:10 PM EST
PRESS RELEASES
Exelixis To Present At The Virtual 39th Annual J.P. Morgan Healthcare Conference On January 11, 2021
By Business Wire
Jan 4, 2021 4:05 PM EST
HEALTH
Best Biotech Stocks to Buy in 2021
By Bret Jensen
Jan 31, 2021 10:15 AM EST
PRESS RELEASES
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival In COSMIC-311 Phase 3 Pivotal Trial In Patients With Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
By Business Wire
Dec 21, 2020 7:30 AM EST
PRESS RELEASES
Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor And Files Investigational New Drug Application For Phase 1 Clinical Trial In Advanced Solid Tumors
By Business Wire
Dec 7, 2020 8:00 AM EST
PRESS RELEASES
Exelixis Announces Partner Takeda Receives Approval In Japan For CABOMETYX® (cabozantinib) For The Treatment Of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
By Business Wire
Nov 27, 2020 8:00 AM EST
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In December
By Business Wire
Nov 23, 2020 5:30 PM EST
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In November
By Business Wire
Nov 2, 2020 4:05 PM EST
PRESS RELEASES
Exelixis Announces Takeda And Ono Submit Supplemental Application For CABOMETYX® (cabozantinib) In Combination With OPDIVO® (nivolumab) For The Treatment Of Unresectable, Advanced Or Metastatic Renal Cell Carcinoma In Japan
By Business Wire
Oct 27, 2020 1:02 AM EDT
PRESS RELEASES
Exelixis Announces First Patient Enrolled In Phase 1 Trial Cohort Evaluating XL092 In Combination With Atezolizumab In Patients With Advanced Solid Tumors
By Business Wire
Oct 26, 2020 8:00 AM EDT
PRESS RELEASES
Exelixis To Release Third Quarter 2020 Financial Results On Thursday, November 5, 2020
By Business Wire
Oct 22, 2020 4:05 PM EDT
PRESS RELEASES
Exelixis And Aurigene Announce That Promising Preclinical Data To Be Presented At The ENA Symposium Support The Clinical Development Of A Novel CDK7 Inhibitor
By Business Wire
Oct 9, 2020 3:02 AM EDT
PRESS RELEASES
Exelixis To Present The Preclinical Profile And Initial Clinical Pharmacokinetics Of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor
By Business Wire
Oct 9, 2020 3:01 AM EDT
PRESS RELEASES
Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts Of The COSMIC-021 Trial Of Cabozantinib In Combination With Atezolizumab
By Business Wire
Sep 21, 2020 10:20 AM EDT
PRESS RELEASES
Exelixis To Host Investor Briefing To Discuss Data Presented At The European Society For Medical Oncology Virtual Congress 2020
By Business Wire
Sep 14, 2020 8:00 AM EDT
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In September
By Business Wire
Sep 8, 2020 4:05 PM EDT
PRESS RELEASES
Exelixis And NBE-Therapeutics Enter Into Exclusive Collaboration And License Option Agreement To Discover And Develop Novel Antibody-Drug Conjugates For The Treatment Of Cancer
By Business Wire
Sep 8, 2020 8:05 AM EDT
PRESS RELEASES
Exelixis And Catalent Enter Into Collaboration, License, And Exclusive Option Agreement To Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
By Business Wire
Sep 8, 2020 8:01 AM EDT
PRESS RELEASES
Exelixis To Release Second Quarter 2020 Financial Results On Thursday, August 6, 2020
By Business Wire
Jul 29, 2020 4:05 PM EDT
